ICOS and neoplasm: Additionally, agonists targeting the inducible T cell co-stimulator (ICOS, CD278) are currently under clinical investigation also for HNSCC, with the aim to, synergistically with anti-PD-1, inhibit the suppressive activity of regulatory T cells and to potentiate the anti-tumor activity of effector T cells [27].